Please assess the completion status of the following clinical trial:

Trial Title: Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the ages of 18-60 of all races and ethnicity.~2. Meets DSM-IV-TR criteria for a primary diagnosis of inattentive or combined type ADHD as diagnosed via the Adult ADHD Clinician Diagnostic Scale~3. For the Sluggish Cognitive Tempo+ group Must Score ≥ 5 items on the Barkley Sluggish Cognitive Tempo Scale; Must be rated 3 (often) or (very often) and total Sluggish Cognitive Tempo symptom score ≥ 26; must have a T-score ≥ 65 on the Metacognition Index and Motivation Subscales of the Behavior RatingInventory of Executive Function - Adult Version (BRIEF-A)~4. Impairment: must have a total score \> 95th percentile on the Barkley Functional Impairment Rating Screen (Barkley Functional Impairment Scale (BFIS).~5. For the Sluggish Cognitive Tempo - group, \< 5 items on the Barkley SCT Scale must be rated 3 (often) or 4 (very often) and total SCT symptom score \< 26; must have a T-score \< 65 on the Metacognition Index and Motivation Subscales of the BRIEF-A.~Exclusion Criteria:~1. Meets DSM-IV-TR criteria for a primary diagnosis of hyperactive-impulsive type ADHD.~2. Any other current psychiatric disorder, determined via the M.I.N.I , which requires pharmacotherapy treatment.~3. Current suicidal ideation or history of suicide attempts, based on the Columbia- Suicide Severity Rating Scale(C-SSRS).~4. Lifetime history of bipolar disorder or any psychotic disorder as per the M.I.N.I~5. Pregnant, breastfeeding or women planning to become pregnant.~6. Positive urine drug toxicology are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine First (Type: EXPERIMENTAL): In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
- Lisdexamfetamine Second (Type: EXPERIMENTAL): In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second

Based on this trial design, predict the completion outcome and termination type (if applicable).